50
Participants
Start Date
June 30, 2015
Primary Completion Date
May 31, 2021
Study Completion Date
June 30, 2021
Pyrotinib
Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
Memorial Sloan Kettering Cancer Center, New York
Florida Cancer Specialists, Sarasota
Tennessee Oncology, Nashville
Henry Ford Health System, Detroit
Washington University, St Louis
South Texas Accelerated Research Therapeutics, San Antonio
University of California, Irvine School of Medicine, Orange
UC Davis Comprehensive Cancer Center, Sacramento
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Hengrui Therapeutics, Inc.
INDUSTRY